177 related articles for article (PubMed ID: 21862166)
1. Associations between the use of metformin, sulphonylureas, or diet alone and cardiovascular outcomes in 6005 people with type 2 diabetes in the FIELD study.
Sullivan D; Forder P; Simes J; Whiting M; Kritharides L; Merrifield A; Donoghoe M; Colman PG; Graham N; Haapamäki H; Keech A;
Diabetes Res Clin Pract; 2011 Nov; 94(2):284-90. PubMed ID: 21862166
[TBL] [Abstract][Full Text] [Related]
2. Sulphonylurea-metformin combination therapy, cardiovascular disease and all-cause mortality: the Fremantle Diabetes Study.
Sillars B; Davis WA; Hirsch IB; Davis TM
Diabetes Obes Metab; 2010 Sep; 12(9):757-65. PubMed ID: 20649627
[TBL] [Abstract][Full Text] [Related]
3. Mortality in type 2 diabetic subjects prescribed metformin and sulphonylurea drugs in combination: cohort study.
Gulliford M; Latinovic R
Diabetes Metab Res Rev; 2004; 20(3):239-45. PubMed ID: 15133756
[TBL] [Abstract][Full Text] [Related]
4. The risk of heart failure in patients with type 2 diabetes treated with oral agent monotherapy.
McAlister FA; Eurich DT; Majumdar SR; Johnson JA
Eur J Heart Fail; 2008 Jul; 10(7):703-8. PubMed ID: 18571471
[TBL] [Abstract][Full Text] [Related]
5. Baseline characteristic differences between patients prescribed sitagliptin vs. other oral antihyperglycemic agents: analysis of a US electronic medical record database.
Zhang Q; Rajagopalan S; Mavros P; Engel SS; Davies MJ; Yin D; Radican L
Curr Med Res Opin; 2010 Jul; 26(7):1697-703. PubMed ID: 20465367
[TBL] [Abstract][Full Text] [Related]
6. Mortality risk with sulphonylureas compared to metformin.
Holden SE; Currie CJ
Diabetes Obes Metab; 2014 Oct; 16(10):885-90. PubMed ID: 24533964
[TBL] [Abstract][Full Text] [Related]
7. Race, ethnicity, and use of thiazolidinediones among US adults with diabetes.
Aquilante CL; Zhang W; McCollum M
Curr Med Res Opin; 2007 Mar; 23(3):489-94. PubMed ID: 17355730
[TBL] [Abstract][Full Text] [Related]
8. Can people with type 2 diabetes live longer than those without? A comparison of mortality in people initiated with metformin or sulphonylurea monotherapy and matched, non-diabetic controls.
Bannister CA; Holden SE; Jenkins-Jones S; Morgan CL; Halcox JP; Schernthaner G; Mukherjee J; Currie CJ
Diabetes Obes Metab; 2014 Nov; 16(11):1165-73. PubMed ID: 25041462
[TBL] [Abstract][Full Text] [Related]
9. Comparison of lipid profiles and lipoprotein a levels in patients with type 2 diabetes mellitus during oral hypoglycemic or insulin therapy.
Habib SS; Aslam M; Naveed AK; Razi MS
Saudi Med J; 2006 Feb; 27(2):174-80. PubMed ID: 16501671
[TBL] [Abstract][Full Text] [Related]
10. Long-term efficacy of metformin therapy in nonobese individuals with type 2 diabetes.
Ong CR; Molyneaux LM; Constantino MI; Twigg SM; Yue DK
Diabetes Care; 2006 Nov; 29(11):2361-4. PubMed ID: 17065668
[TBL] [Abstract][Full Text] [Related]
11. Reduced cardiovascular morbidity and mortality associated with metformin use in subjects with Type 2 diabetes.
Johnson JA; Simpson SH; Toth EL; Majumdar SR
Diabet Med; 2005 Apr; 22(4):497-502. PubMed ID: 15787679
[TBL] [Abstract][Full Text] [Related]
12. Coronary heart disease outcomes in patients receiving antidiabetic agents.
McAfee AT; Koro C; Landon J; Ziyadeh N; Walker AM
Pharmacoepidemiol Drug Saf; 2007 Jul; 16(7):711-25. PubMed ID: 17551989
[TBL] [Abstract][Full Text] [Related]
13. Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trial.
Umpierrez G; Issa M; Vlajnic A
Curr Med Res Opin; 2006 Apr; 22(4):751-9. PubMed ID: 16684436
[TBL] [Abstract][Full Text] [Related]
14. Effects of fenofibrate on cardiovascular events in patients with diabetes, with and without prior cardiovascular disease: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.
Tonkin A; Hunt D; Voysey M; Kesäniemi A; Hamer A; Waites J; Mahar L; Mann S; Glasziou P; Forder P; Simes J; Keech AC;
Am Heart J; 2012 Mar; 163(3):508-14. PubMed ID: 22424024
[TBL] [Abstract][Full Text] [Related]
15. Impact of oral antihyperglycemic therapy on all-cause mortality among patients with diabetes in the Veterans Health Administration.
Kahler KH; Rajan M; Rhoads GG; Safford MM; Demissie K; Lu SE; Pogach LM
Diabetes Care; 2007 Jul; 30(7):1689-93. PubMed ID: 17440170
[TBL] [Abstract][Full Text] [Related]
16. Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy.
Ferrannini E; Fonseca V; Zinman B; Matthews D; Ahrén B; Byiers S; Shao Q; Dejager S
Diabetes Obes Metab; 2009 Feb; 11(2):157-66. PubMed ID: 19125777
[TBL] [Abstract][Full Text] [Related]
17. The effect of pioglitazone as add-on therapy to metformin or sulphonylurea compared to a fixed-dose combination of metformin and glibenclamide on diabetic dyslipidaemia.
Comaschi M; Corsi A; Di Pietro C; Bellatreccia A; Mariz S;
Nutr Metab Cardiovasc Dis; 2008 Jun; 18(5):373-9. PubMed ID: 17919894
[TBL] [Abstract][Full Text] [Related]
18. Impact of adjunctive thiazolidinedione therapy on blood lipid levels and glycemic control in patients with type 2 diabetes.
Peters Harmel AL; Kendall DM; Buse JB; Boyle PJ; Marchetti A; Lau H
Curr Med Res Opin; 2004; 20(2):215-23. PubMed ID: 15006017
[TBL] [Abstract][Full Text] [Related]
19. [Anti-diabetic treatment, insulin resistance and cardiovascular disease in patients with type 2 diabetes].
Hemmingsen B; Lund SS; Vaag A
Ugeskr Laeger; 2009 May; 171(19):1598-602. PubMed ID: 19419642
[TBL] [Abstract][Full Text] [Related]
20. Effects of alpha-glucosidase inhibitor (acarbose) combined with sulfonylurea or sulfonylurea and metformin in treatment of non-insulin-dependent diabetes mellitus.
Vannasaeng S; Ploybutr S; Nitiyanant W; Peerapatdit T; Vichayanrat A
J Med Assoc Thai; 1995 Nov; 78(11):578-85. PubMed ID: 8576667
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
